Loss of an enzyme necessary for a process called lipoylation disrupts the way cancer cells copy their DNA, increasing their vulnerability to a class of anticancer drugs known as PARP inhibitors, a study led by UT Southwestern Medical Center researchers shows.
The Verdict
ClassificationLikely AI
ConfidenceHigh confidence
Analyzedtext, image
ImageAI Generated
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/0bff6085-bb65-427f-9ef5-df39c33b8936)